Novo Nordisk A/S (NVO)
| Bid | 68.95 |
| Market Cap | 293.83B |
| Revenue (ttm) | 290.4B |
| Net Income (ttm) | 100.99B |
| EPS (ttm) | 3.44 |
| PE Ratio (ttm) | 19.33 |
| Forward PE | 1.82 |
| Analyst | Buy |
| Ask | 69.03 |
| Volume | 8,828,384 |
| Avg. Volume (20D) | 8,735,773 |
| Open | 66.47 |
| Previous Close | 65.16 |
| Day's Range | 65.41 - 66.64 |
| 52-Week Range | 57.00 - 148.15 |
| Beta | 0.25 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy...
Analyst Forecast
According to 4 analyst ratings, the average rating for NVO stock is "Buy." The 12-month stock price forecast is $160, which is an increase of 140.57% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago · https://247wallst.com
S&P 500 (VOO) Live: Trump Administration Blasts Amazon.com, and the S&P 500 TumblesLive Updates Live Coverage Has Ended S&P 500 Extends Its Winning Streak 4:18 pm The S&P 500 closed up 0.6% for Tuesday, extending its winning streak to six straight days. Trade Talks Keep S&am...
